Alirocumab

Alirocumab?
Monoclonal antibody
Source Human
Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Clinical data
Trade names Praluent
  • Investigational
Subcutaneous injection
Identifiers
1245916-14-6
None
Chemical data
Formula C6472H9996N1736O2032S42
146.0 kDa

Alirocumab (trade name Praluent) is an experimental human monoclonal antibody PCSK9 inhibitor designed for the treatment of hypercholesterolemia.[1] It is also known as REGN727 and SAR236553.[2] It was discovered by Regeneron Pharmaceuticals and is being co-developed with Sanofi. A main competitor in the race to worldwide health authority approval is evolocumab in development by Amgen.

Clinical trials

A phase 3 trial of statin intolerant patients called ODYSSEY ran for 65 weeks.[3] Results were presented at the 2014 European Society of Cardiology meeting.[4]

References

  1. ↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization
  2. ↑ Sheridan, C (2013). "Phase 3 data for PCSK9 inhibitor wows". Nature Biotechnology 31 (12): 1057–8. doi:10.1038/nbt1213-1057. PMID 24316621.
  3. ↑ "Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.". Journal of Clinical Lipidology 8: 554–61. Nov–Dec 2014. doi:10.1016/j.jacl.2014.09.007. PMID 25499937.
  4. ↑ "Huge Decreases in LDL Cholesterol With Alirocumab: ODYSSEY".